Currently viewing the tag: "colorectal cancer"

Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer.

The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling […]

Continue Reading